Drug Profile
Research programme: bromodomain inhibitors - Roche
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Tensha Therapeutics
- Developer Roche
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Nov 2013 Preclinical development is ongoing in the US
- 13 Sep 2011 Preclinical trials in Cancer in USA (unspecified route)